This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
SUNNYVALE, Calif., June 30, 2010 (GLOBE NEWSWIRE) -- Arrayit Corporation (OTCBB:ARYC), a leader in life sciences and healthcare technology, announced today that the company has received a registered trademark Notice of Allowance from the United States Patent and Trademark Office (USPTO) for the company's OvaDx® pre-symptomatic ovarian cancer test. The June 29
th, 2010 issuance of USPTO serial number 77891798 grants Arrayit exclusive nationwide rights to use the mark on or in connection with scientific, research, medical laboratory and clinical diagnostics uses of OvaDx® for the full lifetime of the product.
Arrayit's OvaDx®, the market's first comprehensive diagnostic screening test for ovarian cancer, uses approximately 100 proteomic biomarkers to identify molecular beacons of ovarian cancer that accumulate in the bloodstream as soon as an ovarian tumor begins to develop. OvaDx® detects both early and late stage ovarian cancer with high sensitivity and specificity using Arrayit's proprietary microarrays, which are tiny medical devices that screen large numbers of patient samples in a highly miniaturized and automated manner. OvaDx® leverages Arrayit's patented manufacturing technology and will be marketed and sold upon FDA approval by the company's subsidiary Arrayit Diagnostics, Inc.
Arrayit CEO Rene Schena states, "We are pleased to receive a Notice of Allowance from the USPTO regarding our registered trademark. This achievement marks another important step in the commercialization of OvaDx®."
About Arrayit Corporation
Arrayit Corporation, headquartered in Sunnyvale, California, leads and empowers the genetic, research, pharmaceutical, and diagnostic communities through the discovery, development and manufacture of proprietary life science technologies and consumables for disease prevention, treatment and cure. Arrayit now offers over 650 products and services to a customer base of more than 10,000 clinics and research facilities and more than 5,000 laboratories worldwide, including most every major university, pharmaceutical and biotech company, major agricultural and chemical company, government agency, national research foundation and many private sector enterprises. Please visit
www.arrayit.com for more information.
About Arrayit Diagnostics, Inc.
Arrayit Diagnostics, Inc., a majority‐owned subsidiary of Arrayit Corporation, is actively engaged in marketing and commercializing proprietary microarray‐based diagnostic tests for early stage pre-symptomatic detection of ovarian and prostate cancer, neurodegenerative diseases, and other chronic and severe disease states.